---
title: "Cleerly receives US FDA breakthrough designation for CAD staging system"
date: "2024-03-07T12:20:50.000Z"
publishedDate: "7 mars 2024"
summary: "Cleerly has been granted breakthrough device designation by the US Food and Drug Administration (FDA) for its coronary artery disease (CAD) staging system. The CAD Staging System is a non-invasive imaging-based investigational software device that analyses important and actionable features of coronary atherosclerosis, stenosis and ischaemia."
importance: ""
sourceUrl: "https://cardiovascularnews.com/cleerly-receives-us-fda-breakthrough-designation-for-cad-staging-system/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2024-03-07-cleerly-receives-us-fda-breakthrough-designation-for-cad-staging-system"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2017/02/Coronary-angioplasty-thinkstock.png"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/cleerly-receives-us-fda-breakthrough-designation-for-cad-staging-system/"
---

![Cleerly receives US FDA breakthrough designation for CAD staging system](https://cardiovascularnews.com/wp-content/uploads/sites/14/2017/02/Coronary-angioplasty-thinkstock.png)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/cleerly-receives-us-fda-breakthrough-designation-for-cad-staging-system/*

## L’essentiel

Cleerly has been granted breakthrough device designation by the US Food and Drug Administration (FDA) for its coronary artery disease (CAD) staging system. The CAD Staging System is a non-invasive imaging-based investigational software device that analyses important and actionable features of coronary atherosclerosis, stenosis and ischaemia.

## Lien source

https://cardiovascularnews.com/cleerly-receives-us-fda-breakthrough-designation-for-cad-staging-system/
